GnRH antagonist vs long agonist protocols for ART have been examined for efficacy and safety outcomes with support for lower incidence of ovarian hyperstimulation syndrome (OHSS) with GnRH antagonist protocols [14–16]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.